3 Undervalued Growth Stocks to Double Your Wealth in 2024

In This Article:

While a certain confidence in betting with the masses exist, investors wanting to up the ante may consider undervalued growth stocks. To better frame the discussion, it’s useful to consider the sport of baseball.

Generally speaking, managers – especially of the old school variety – prefer disciplined at-bats. In other words, good things happen with (good) contact. Sure, you can take a monster hack at a pitch. However, the consequences of getting it just wrong (i.e. a pop-up or a quick one-hop grounder to the shortstop) can be devastating.

Of course, when you’re down a few runs late in the game, you may not have the luxury of playing small ball. And that’s the allure of growth stocks with 2X potential. With one swing of the bat, the entire complex of the matchup can change.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Still, you must accept that higher-reward securities almost always carry greater risk. If you can handle the heat, these undervalued growth stocks could double your money next year.

Pfizer (PFE)

blue Pfizer logo on the windows of a corporate building PFR stock
blue Pfizer logo on the windows of a corporate building PFR stock

Source: photobyphm / Shutterstock.com

A simultaneously risky but also compelling opportunity among growth stocks with 2X potential, Pfizer (NYSE:PFE) during the early period of the Covid-19 crisis naturally benefited. As one of the leading providers of the vaccine against the SARS-CoV-2 virus, Pfizer’s share price skyrocketed into late 2021. Since then, however, PFE lost its mojo. Since the January opener, it stumbled more than 43%.

Contrarians might regard the red ink as a possible candidate for undervalued growth stocks with doubling potential. First, PFE trades with a forward earnings multiple of 8.82x, well lower than the sector median of 14.31x. Additionally, the market rates shares at a price/earnings-to-growth (PEG) ratio of only 0.47X. In contrast, the sector median stands at 1.81x.

Of course, Pfizer will probably have to leverage its messenger-RNA acumen to reinvigorate sentiment. Fortunately, analysts are willing to take that bet, rating PFE a moderate buy with a $39 price target. Further, the high-side target stands at $75, implying nearly 159% upside potential.

VAALCO Energy (EGY)

Panorama of Oil and Gas central processing platform in twilight, offshore hard work occupation twenty four working hours. Best oil stocks to buy
Panorama of Oil and Gas central processing platform in twilight, offshore hard work occupation twenty four working hours. Best oil stocks to buy

Source: Oil and Gas Photographer / Shutterstock.com

As a hydrocarbon energy exploration (upstream) specialist, VAALCO Energy (NYSE:EGY) possibly faces relevancy risks. After all, the broader social and political winds favor clean and renewable energy integration and proliferation. However, EGY could be an attractive (albeit speculative) idea among undervalued growth stocks based on fundamentals. Amid escalating geopolitical tensions, hydrocarbon demand in the intermediate term should rise.